Back to top
more

Citius Pharmaceuticals (CTXR)

(Delayed Data from NSDQ)

$0.77 USD

0.77
673,739

+0.07 (9.61%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $0.76 -0.01 (-0.95%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CTXR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Citius Pharmaceuticals, Inc. [CTXR]

Reports for Purchase

Showing records 1 - 20 ( 73 total )

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

04/01/2024

Daily Note

Pages: 5

Termination of Coverage

Provider: Dawson James Securities, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

02/23/2024

Company Report

Pages: 5

Fiscal 1Q24 Report Points to a Pivotal Year Ahead for Lymphir, Mino-Lok and Halo-Lido

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

02/15/2024

Company Report

Pages: 5

BUY: Reports the Quarter, $20M in Cash, Summer Runway

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

02/14/2024

Company Report

Pages: 5

BUY: Resubmits the BLA for LYMPHIR for CTCL

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

02/14/2024

Company Report

Pages: 4

Lymphir BLA Resubmitted; FDA Requirements Addressed; Reiterate Buy and $4 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

01/31/2024

Company Report

Pages: 5

BUY: Citius vs. CorMedix (CRMD-Not Rated): How is Mino-Lok Different versus DefenCath?

Provider: Dawson James Securities, Inc.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

01/16/2024

Company Report

Pages: 5

New Year Begins With a Pivotal Milestone; Reiterate Buy and $4 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

01/11/2024

Company Report

Pages: 5

BUY: Citius Completes Enrollment In Pivotal Phase 3 Trial Of Mino-Lok To Salvage Catheters

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

01/02/2024

Company Report

Pages: 5

BUY: Reports 2023 Results: $37M Spent, $25M in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

11/02/2023

Company Report

Pages: 5

BUY: LYMPHIR + PD1 Appears to Enhance Efficacy

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

10/24/2023

Company Report

Pages: 5

BUY: Merger of TenX (SPAC) LYMPHIR to NEWCO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

09/11/2023

Company Report

Pages: 5

BUY: Receives FDA Guidance - Resubmission of LYMPHIR

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

08/15/2023

Company Report

Pages: 5

BUY: 92 Event Threshold Likely Achieved in Mino-Lok Trial

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

08/10/2023

Daily Note

Pages: 3

Mino-Lok Phase 3 Reaches 92 Events

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

08/01/2023

Company Report

Pages: 5

CRL for Lymphir BLA Only Delays its Approval; Reiterate Buy With New $4 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

07/31/2023

Company Report

Pages: 5

BUY: I/ONTAK (E7777-LYMPHIR) Hits a Speed Bump

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

06/21/2023

Company Report

Pages: 5

BUY: Halo-Lido: A Meaningful Reduction in Symptom Severity -Hemorrhoids Not Factored into our Model.

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

05/30/2023

Company Report

Pages: 4

Looking for a Positive I/ONTAK Decision to Maximize Untapped Value; Reiterate Buy Rating and $6 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

05/18/2023

Company Report

Pages: 5

BUY: Reports the Quarter - Mino-Lok and I/ONTAK Updates

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Citius Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

05/04/2023

Company Report

Pages: 5

BUY: Raises Capital but just $15M @ Discount + 5YR Warrants - Lowering PT from $10.0 to $8.0

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party